What it is
Anti-amyloid antibodies are designed to target amyloid beta biology in Alzheimer disease.[3,1]
Why it matters
FDA materials describe approved anti-amyloid treatments for adults with Alzheimer disease in early disease contexts, with slowing of disease progression rather than restoration of lost function.[1,2]
What it affects
- FDA donanemab approval information described patients with confirmed amyloid pathology and mild cognitive impairment or mild dementia stage of disease.[1]